HALEOS LABS LIMITED
HALEOS LABS LIMITED operates in Pharmaceuticals, part of the Healthcare sector. It booked ₹73 cr of revenue in its latest quarter (Q1 FY27) and kept 3.6% of sales as profit.
“Your Company is a net exporter, hence doesn’t fell the requirement of hedging. 14.”
Healthier than 45% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 81–150 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 51
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
What if I invest in HALEOSLABS?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹73 cr |
| Other Income | ₹46.3 L |
| Total Income | ₹73 cr |
| Cost of Materials | ₹40 cr |
| Purchases of Stock-in-Trade | ₹-14 cr |
| Employee Benefit Expense | ₹18 cr |
| Finance Costs | ₹2 cr |
| Depreciation & Amortisation | ₹4 cr |
| Other Expenses | ₹20 cr |
| Total Expenses | ₹70 cr |
| Profit before Tax | ₹3 cr |
| Tax Expense | ₹2 cr |
| Net Profit | ₹2 cr |
| Net margin on total income | 2.5% |
| Metric | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 95 cr | 75 cr | 73 cr |
| Total income | 95 cr | 77 cr | 73 cr |
| Expenses | 86 cr | 76 cr | 70 cr |
| Profit before tax | 9 cr | 90.6 L | 3 cr |
| Tax | 2 cr | 56.2 L | 2 cr |
| Net profit (owners' share) | 7 cr | 43.6 L | 3 cr |
| Net margin (owners' share, on revenue) | 7.0% | 0.6% | 3.6% |
| EPS (₹) | 21.89 | 1.44 | 8.75 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹1,867 | ₹4.48 L cr | 38.6 | 13.9% | 18.9% | — |
| Divi's Laboratories Limited | ₹9,323 | ₹2.47 L cr | 68.7 | 21.5% | 29.3% | — |
| Torrent Pharmaceuticals Limited | ₹4,875 | ₹1.65 L cr | 82.0 | 27.0% | 11.5% | — |
| Zydus Lifesciences Limited | ₹1,135 | ₹1.13 L cr | 30.4 | 13.9% | 11.7% | — |
| Cipla Limited | ₹1,376 | ₹1.11 L cr | 35.2 | 9.2% | 11.1% | — |
| Laurus Labs Limited | ₹1,948 | ₹1.05 L cr | 71.5 | 27.7% | 18.1% | — |
| Dr. Reddy's Laboratories Limited | ₹1,175 | ₹98,113 cr | 55.1 | 4.7% | 5.5% | — |
| Aurobindo Pharma Limited | ₹1,690 | ₹97,243 cr | 23.7 | 10.9% | 11.3% | — |
| Lupin Limited | ₹2,098 | ₹95,936 cr | 16.9 | 25.2% | 17.1% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹1.5 / share | 24 Sep 2025 |
| Dividend | ₹1.5 / share | 23 Sep 2024 |
| Dividend | ₹1.5 / share | 22 Sep 2023 |
| Dividend | ₹1.5 / share | 22 Sep 2022 |
| Dividend | ₹1.5 / share | 20 Sep 2021 |
| Dividend | ₹1.5 / share | 19 Sep 2019 |
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.